131 related articles for article (PubMed ID: 29020542)
1. Fairness and Transparency in an Expanded Access Program: Allocation of the Only Treatment for SMA1.
Burgart AM; Collier J; Cho MK
Am J Bioeth; 2017 Oct; 17(10):71-73. PubMed ID: 29020542
[No Abstract] [Full Text] [Related]
2. Is There a 'Right to Try' Experimental Therapies? Ethical Criteria for Selecting Patients With Spinal Muscular Atrophy to Receive Nusinersen in an Expanded Access Program.
Jecker NS
Am J Bioeth; 2017 Oct; 17(10):70-71. PubMed ID: 29020544
[No Abstract] [Full Text] [Related]
3. Expanded Access for Nusinersen in Patients With Spinal Muscular Atropy: Negotiating Limited Data, Limited Alternative Treatments, and Limited Hospital Resources.
Wilfond BS; Morales C; Taylor HA
Am J Bioeth; 2017 Oct; 17(10):66-67. PubMed ID: 29020560
[No Abstract] [Full Text] [Related]
4. Hard Choices for Vulnerable Patients: Some Lessons Learned That May Apply.
Kearns L; Caplan AL
Am J Bioeth; 2017 Oct; 17(10):68-69. PubMed ID: 29020543
[No Abstract] [Full Text] [Related]
5. Implementing a Global Expanded Access Program (EAP) for Infantile-Onset Spinal Muscular Atrophy (Type I): Understanding the Imperative, Impact and Challenges.
Yong J; Moffett M; Lucas S
J Neuromuscul Dis; 2019; 6(2):227-231. PubMed ID: 31127730
[TBL] [Abstract][Full Text] [Related]
6. A new respiratory scoring system for evaluation of respiratory outcomes in children with spinal muscular atrophy type1 (SMA1) on SMN enhancing drugs.
Edel L; Grime C; Robinson V; Manzur A; Abel F; Munot P; Ridout D; Scoto M; Muntoni F; Chan E
Neuromuscul Disord; 2021 Apr; 31(4):300-309. PubMed ID: 33752934
[TBL] [Abstract][Full Text] [Related]
7. Food and Drug Administration responds to pressure for expanded drug access.
Brower V
J Natl Cancer Inst; 2014 Jun; 106(6):dju171. PubMed ID: 24907387
[No Abstract] [Full Text] [Related]
8. Questions of Safety and Fairness Raised as Right-to-Try Movement Gains Steam.
Jacob JA
JAMA; 2015 Aug; 314(8):758-60. PubMed ID: 26244653
[No Abstract] [Full Text] [Related]
9. Rationing, inefficiency and the role of clinicians.
Voigt K
J Med Ethics; 2014 Feb; 40(2):94-6. PubMed ID: 24293636
[No Abstract] [Full Text] [Related]
10. Stem-cell ruling riles researchers.
Abbott A
Nature; 2013 Mar; 495(7442):418-9. PubMed ID: 23538801
[No Abstract] [Full Text] [Related]
11. Access to 'investigational' cancer drugs: perspective of a trainee.
Kuo JC
Intern Med J; 2015 Feb; 45(2):235. PubMed ID: 25650544
[No Abstract] [Full Text] [Related]
12. Ethical perspectives about organ allocation for transplantation.
Houssin D
Acta Gastroenterol Belg; 2004; 67(2):168-71. PubMed ID: 15285572
[TBL] [Abstract][Full Text] [Related]
13. Dilemmas in the compassionate supply of investigational cancer drugs.
Lewis JR; Lipworth W; Kerridge I; Doran E
Intern Med J; 2014 Sep; 44(9):841-5. PubMed ID: 25201421
[TBL] [Abstract][Full Text] [Related]
14. Balancing principles, QALYs, and the straw men of resource allocation.
McMillan J; Hope T
Am J Bioeth; 2010 Apr; 10(4):48-50. PubMed ID: 20379922
[No Abstract] [Full Text] [Related]
15. Priority to the young or to those with least lifetime health?
Norheim OF
Am J Bioeth; 2010 Apr; 10(4):60-1. PubMed ID: 20379928
[No Abstract] [Full Text] [Related]
16. Distributive justice in a bad economy: some thoughts on ethics of care.
Williams DL
J Forensic Nurs; 2009; 5(3):183-4. PubMed ID: 19702745
[No Abstract] [Full Text] [Related]
17. Buying time: doctors debate the ethics of care and cost.
Jauhar S
N Y Times Web; 2003 May; ():F5. PubMed ID: 12812163
[No Abstract] [Full Text] [Related]
18. Dueling ethical frameworks for allocating health resources.
Vawter DE; Garrett JE; Gervais KG; Prehn AW; DeBruin DA
Am J Bioeth; 2010 Apr; 10(4):54-6. PubMed ID: 20379925
[No Abstract] [Full Text] [Related]
19. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
[TBL] [Abstract][Full Text] [Related]
20. Complete lives, incomplete theories.
Friedman A
Am J Bioeth; 2010 Apr; 10(4):58-60. PubMed ID: 20379927
[No Abstract] [Full Text] [Related]
[Next] [New Search]
